A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
Clinical trial NCT03482011 · COMPLETED
Trial details
- NCT number
- NCT03482011
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-24
- Primary completion
- 2019-03-21
- Enrollment
- 530
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.